ATE457731T1 - Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma - Google Patents

Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma

Info

Publication number
ATE457731T1
ATE457731T1 AT06769626T AT06769626T ATE457731T1 AT E457731 T1 ATE457731 T1 AT E457731T1 AT 06769626 T AT06769626 T AT 06769626T AT 06769626 T AT06769626 T AT 06769626T AT E457731 T1 ATE457731 T1 AT E457731T1
Authority
AT
Austria
Prior art keywords
copd
asthma
compounds
treatment
combination
Prior art date
Application number
AT06769626T
Other languages
English (en)
Inventor
Tomas Eriksson
Johan Hansson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37771856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE457731(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE457731T1 publication Critical patent/ATE457731T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06769626T 2005-08-26 2006-08-24 Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma ATE457731T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0501896 2005-08-26
SE0601220 2006-06-01
PCT/SE2006/000970 WO2007024182A1 (en) 2005-08-26 2006-08-24 A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma.

Publications (1)

Publication Number Publication Date
ATE457731T1 true ATE457731T1 (de) 2010-03-15

Family

ID=37771856

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06769626T ATE457731T1 (de) 2005-08-26 2006-08-24 Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma

Country Status (19)

Country Link
US (1) US20090215732A1 (de)
EP (1) EP1922074B1 (de)
JP (1) JP2009506028A (de)
KR (1) KR20080038361A (de)
AR (1) AR055614A1 (de)
AT (1) ATE457731T1 (de)
AU (2) AU2006282121B2 (de)
BR (1) BRPI0615110A2 (de)
CA (1) CA2620847A1 (de)
DE (1) DE602006012332D1 (de)
EC (1) ECSP088287A (de)
HK (1) HK1116095A1 (de)
IL (2) IL189195A0 (de)
MX (1) MX2008002321A (de)
NO (1) NO20081480L (de)
RU (1) RU2414222C2 (de)
TW (1) TW200744612A (de)
UY (1) UY29760A1 (de)
WO (1) WO2007024182A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
WO2008103125A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
US20110124613A1 (en) * 2007-02-23 2011-05-26 Tomas Eriksson Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
WO2009142588A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) a chemokine receptor 1 (ccr1) antagonist and (b) glucocorticoid receptor modulator
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
CN103874483B (zh) 2011-10-11 2017-09-12 奇斯药制品公司 包衣了脂肪酸的β‑激动剂的晶体微粒
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
EP4181942A4 (de) * 2020-07-28 2024-10-02 Susavion Biosciences Inc Verfahren zur behandlung von neutrophil-gesteuerten entzündlichen erkrankungen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (de) * 1972-05-19 1975-08-18 Bofors Ab
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
JP2004516238A (ja) * 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのｎ−ウレイドアルキル−ピペリジン
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
CA2445839A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US20060183731A1 (en) * 2003-07-15 2006-08-17 Min Ge 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity

Also Published As

Publication number Publication date
EP1922074B1 (de) 2010-02-17
AR055614A1 (es) 2007-08-29
US20090215732A1 (en) 2009-08-27
TW200744612A (en) 2007-12-16
UY29760A1 (es) 2007-03-30
AU2006282121A1 (en) 2007-03-01
HK1116095A1 (en) 2008-12-19
DE602006012332D1 (de) 2010-04-01
ECSP088287A (es) 2008-04-28
BRPI0615110A2 (pt) 2011-05-03
CA2620847A1 (en) 2007-03-01
EP1922074A1 (de) 2008-05-21
WO2007024182A1 (en) 2007-03-01
MX2008002321A (es) 2008-03-14
IL189195A0 (en) 2008-08-07
KR20080038361A (ko) 2008-05-06
NO20081480L (no) 2008-05-16
RU2414222C2 (ru) 2011-03-20
AU2009202925B2 (en) 2011-04-28
IL199022A0 (en) 2010-02-17
JP2009506028A (ja) 2009-02-12
RU2008108175A (ru) 2009-10-10
AU2006282121B2 (en) 2009-12-24
AU2009202925A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
ATE457731T1 (de) Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma
EP1865967A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung viraler infektionen und anderer erkrankungen
IL189500A (en) 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p
DE602005019416D1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
HK1114013A1 (en) The combination of anticholinergics and leukotriene receptor antagonists for the treatment of repiratory diseases
JP2008513510A5 (de)
JP2010513478A5 (de)
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
IL182010A0 (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
EP1928453A4 (de) Verfahren und zusammensetzungen zur prävention und behandlung von nierenerkrankungen
EP2124921A4 (de) Sulfonyl-semicarbazide, carbonyl-semicarbazide, semicarbazide und harnstoffe, pharmazeutische zusammensetzungen daraus sowie verfahren zur behandlung hämorrhagischer fieberviren einschliesslich mit arenaviren behandelter infektionen
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
ATE517877T1 (de) Neue arzneimittel zur behandlung von atemwegserkrankungen
HK1137357A1 (en) Use of a composition comprising formoterol and beclometasone dipropionate in the manufacture of a pharmaceutical for the prevention and or treatment of an exacerbation of asthma
ATE361076T1 (de) Kombination von loteprednoletabonat und dfho zur behandlung von atemwegserkrankungen, allergischen erkrankungen, asthma und copd
IL197783A (en) Polycyclic compounds, preparations containing them and polycyclic compounds for use in the treatment of synthetic respiratory virus infections
EP2120935A4 (de) Neue kombination von verbindungen zur verwendung bei der behandlung von atemwegserkrankungen, insbesondere chronisch obstruktiver lungenerkrankung (copd) und asthma
EP1945613A4 (de) Neue, für die behandlung von copd und asthma geeignete 1-benzyl-4-piperidinamine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties